Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development FDAThe U.S.RegulatoryGene Therapy PlatformRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) FDA The U.S. RegulatoryGene Therapy PlatformRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA renews criticism of trial sponsors over transparencyNext: Lilly investing billions to prepare for overseas oral GLP-1 launches Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
